ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularsubjectleftplaceboscreening
  Phrases that lowered it: aminotransferaseupperpatientsmmreceptor
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.8% (raises risk) · Sponsor's track record
• Minimum age: 35 (lowers risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 31.0% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 40 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 98.7% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, respiratory: Yes (raises risk) · Disease area
• Maximum age: 80 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF NCT00768300 · started 2008 · scored riskier than 43% of active trials terminated
• Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension NCT02951429 · started 2016 · scored riskier than 47% of active trials completed
• Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) NCT03955146 · started 2019 · scored riskier than 55% of active trials terminated
• Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial NCT01224210 · started 2010 · scored riskier than 79% of active trials completed
• Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis NCT02345070 · started 2015 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.